ArticleBMJ (Clinical research ed.)2006
Screening strategies for chronic kidney disease in the general population: follow-up of cross sectional health survey.
Article in BMJ (Clinical research ed.), 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 97 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
97 citing papers in PubMed, 4 syntheses or guidelines pooled it, 328 citations in OpenAlex.
- Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for adults with early (stage 1 to 3) non-diabetic chronic kidney disease.The Cochrane database of systematic reviews · 2023Pooled it
- Effect of antiplatelet therapy on cardiovascular and kidney outcomes in patients with chronic kidney disease: a systematic review and meta-analysis.BMC nephrology · 2019Pooled it
- Pooled it
- Associations of estimated glomerular filtration rate and albuminuria with mortality and renal failure by sex: a meta-analysis.BMJ (Clinical research ed.) · 2013Pooled it
- Benefits of aldosterone receptor antagonism in chronic kidney disease: the BARACK-D RCT.Health technology assessment (Winchester, England) · 2025Trial
- Trial
- Association between moderate renal insufficiency and cardiovascular events in a general population: Tehran lipid and glucose study.BMC nephrology · 2012Trial
- Optimal patient care in advanced chronic kidney disease progressing to kidney failure.Nature reviews. Nephrology · 2026Review
- Clinical risk factors associated with rapid renal function decline after nephrectomy.BMC cancer · 2026Article
- Article
- Sodium Intake Estimation in Chronic Kidney Disease: From Measurement Methods to Clinical Outcomes.Turkish journal of nephrology · 2025Article
- Screening chronic kidney disease through deep learning utilizing ultra-wide-field fundus images.NPJ digital medicine · 2024Article
- Article
- Association between systemic immune-inflammation index and chronic kidney disease: A population-based study.PloS one · 2024Article
- The national trend of the burden of Chronic Kidney Disease (CKD) in Iran from 1990 to 2019.Journal of diabetes and metabolic disorders · 2023Article
- Current progress in artificial intelligence-assisted medical image analysis for chronic kidney disease: A literature review.Computational and structural biotechnology journal · 2023Review
- Kidney trajectory charts to assist general practitioners in the assessment of patients with reduced kidney function: a randomised vignette study.BMJ evidence-based medicine · 2022Article
- External validation of six clinical models for prediction of chronic kidney disease in a German population.BMC nephrology · 2022Article
- Early Identification of CKD-A Scoping Review of the Global Populations.Kidney international reports · 2022Article
- Article
37 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
7 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo find an effective screening strategy for detecting patients with chronic kidney disease and to describe the natural course of the disease.
designEight year follow-up of a cross sectional health survey (the HUNT II study).
settingNord-Trøndelag County, Norway
participants65,604 people (70.6 % of all adults aged >or=20 in the county).
main outcome measuresIncident end stage renal disease (ESRD) and cardiovascular mortality monitored by individual linkage to central registries.
results3069/65,604 (4.7%) people had chronic kidney disease (estimated glomerular filtration rate <60 ml/min/1.73 m(2)), so we would need to screen 20.6 people (95% confidence interval 20.0 to 21.2) to identify one case. Restriction of screening to those with hypertension, diabetes, or age >55 would identify 93.2% (92.4% to 94.0%) of patients with chronic kidney disease, with a number needed to screen of 8.7 (8.5 to 9.0). Restriction of screening according to guidelines of the United States kidney disease outcomes quality initiative (US KDOQI) gave similar results, but restriction according to the United Kingdom's chronic kidney disease guidelines detected only 60.9% (59.1% to 62.8%) of cases. Screening only people with previously known diabetes or hypertension detected 44.2% (42.7% to 45.7%) of all cases, with a number needed to screen of six. During the eight year follow-up only 38 of the 3069 people with chronic kidney disease progressed to end stage renal disease, and the risk was especially low in people without diabetes or hypertension, women, and those aged >or=70 or with a glomerular filtration rate 45-59 ml/min/1.73 m(2) at screening. In contrast, there was a high cardiovascular mortality: 3.5, 7.4, and 10.1 deaths per 100 person years among people with a glomerular filtration rate 45-59, 30-44, and <30 ml/min/1.73 m(2), respectively.
conclusionScreening people with hypertension, diabetes mellitus, or age >55 was the most effective strategy to detect patients with chronic kidney disease, but the risk of end stage renal disease among those detected was low.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.